Royalty Report: Drugs, Pharmaceuticals, Pain – Collection: 262058

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Pharmaceuticals
  • Pain

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 262058

License Grant
The Licensors, four  individuals, entered into a royalty agreement with the Licensee, which, in part, replaces the royalty agreement dated 2014.
License Property
Founders will receive a royalty on all over the counter, non-prescription and/or nutritional supplement products  that are marketed to stop, prevent, relieve or otherwise treat muscle cramps, muscle soreness, or aid in muscle recovery and incorporate the intellectual property.  The product must also include at least one ion channel activator.

“Product” shall mean, except as provided below, (a) any and all products sold by the Company and its Affiliates for use in the treatment of any neuromuscular disorders, including any anti-cramp products, that use, incorporate or embody (or are made using) any intellectual property (including any know-how) or other material assets that are or were owned by or licensed to the Company and (b) any and all products sold by a Licensee for use in the treatment of any neuromuscular disorders, including any anti-cramp products, that use, incorporate or embody (or are made using) any intellectual property (including any know-how) or other material assets that were owned by or licensed to the Company and licensed from the Company or any of its Affiliates to such Licensee.

Field of Use
This agreement pertains to the healthcare industry.

IPSCIO Record ID: 4689

License Grant
In connection with the transfer of certain intellectual property by the scientific founders of the Licensee, the Licensee pursuant to a royalty agreement, is obligated to pay the Founders (Licensor) a royalty on the gross sales of any product sold by them or by any of their licensees for use in the treatment of any neuromuscular disorders, and that uses, incorporates or embodies, or made using any of the intellectual property, including any know-how.
License Property
“Product” shall mean, except as provided below, (a) any and all products sold by the Company and its Affiliates for use in the treatment of any neuromuscular disorders, including any anti-cramp products, that use, incorporate or embody (or are made using) any intellectual property (including any know-how) or other material assets that are or were owned by or licensed to the Company and (b) any and all products sold by a Licensee for use in the treatment of any neuromuscular disorders, including any anti-cramp products, that use, incorporate or embody (or are made using) any intellectual property (including any know-how) or other material assets that were owned by or licensed to the Company and licensed from the Company or any of its Affiliates to such Licensee.
Field of Use
The newly formed Licensee is a biotechnology company that is developing proprietary treatments for nocturnal leg cramps and spasms associated with severe neuromuscular conditions. The premise is that activation of certain receptors in primary sensory neurons reduces the repetitive firing, or hyperexcitability, of alpha-motor neurons, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms.  They are initially focused on a drug development effort to treat nocturnal leg cramps.

IPSCIO Record ID: 3561

License Grant
The Licensors will be paid a royalty on any product sold by Licensee for use in the treatment of any neuromuscular disorder, and that uses, incorporates or embodies (or is made using) any of the intellectual property (including any know-how).
License Property
The Licensee is a biotechnology company that is developing proprietary treatments for nocturnal leg cramps and spasms associated with severe neuromuscular conditions. Novel insights regarding neuromuscular physiology from the Licensors form the basis of the development efforts.

Nocturnal leg cramps are pains that occur in the legs during the night. They usually cause awakenings from sleep, but they may also occur while awake at night during periods of inactivity. These cramps are most often present in the calf muscles but can also occur in the thighs or feet.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.